Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2025-2031

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2025-2031

The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is predicted to grow from US$ 105770 million in 2025 to US$ 410560 million in 2031; it is expected to grow at a CAGR of 25.4% from 2025 to 2031.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:

Market Drivers:

Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.

Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.

Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.

Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.

Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.

Market Challenges:

High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.

Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.

Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.

Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.

Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.

Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.

LP Information, Inc. (LPI) ' newest research report, the “Glucagon Like Peptide-1 (GLP-1) Agonists Industry Forecast” looks at past sales and reviews total world Glucagon Like Peptide-1 (GLP-1) Agonists sales in 2024, providing a comprehensive analysis by region and market sector of projected Glucagon Like Peptide-1 (GLP-1) Agonists sales for 2025 through 2031. With Glucagon Like Peptide-1 (GLP-1) Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon Like Peptide-1 (GLP-1) Agonists industry.

This Insight Report provides a comprehensive analysis of the global Glucagon Like Peptide-1 (GLP-1) Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon Like Peptide-1 (GLP-1) Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Glucagon Like Peptide-1 (GLP-1) Agonists market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon Like Peptide-1 (GLP-1) Agonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon Like Peptide-1 (GLP-1) Agonists.

This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon Like Peptide-1 (GLP-1) Agonists market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other

Segmentation by Application:
Diabetes
Obesity

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae

Key Questions Addressed in this Report

What is the 10-year outlook for the global Glucagon Like Peptide-1 (GLP-1) Agonists market?

What factors are driving Glucagon Like Peptide-1 (GLP-1) Agonists market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Glucagon Like Peptide-1 (GLP-1) Agonists market opportunities vary by end market size?

How does Glucagon Like Peptide-1 (GLP-1) Agonists break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.